Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with com
Less than a year after joining with OxfordVR to create a specialist in digital therapeutics (DTx) for mental illnesses, BehaVR has expanded into the chronic pain category
Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the
Sword Health has extended its range of digital interventions for health conditions with the launch of an artificial intelligence-powered programme that can help predict wh
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.